Latest News for: roche holding ag

Edit

Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD) (Roche Holding AG)

Public Technologies 01 Aug 2025
Roche Holding AG published this content on August 01, 2025, and is solely ...
Edit

Genentech and Roche Present New Insights in Alzheimer’s Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC (Roche Holding AG)

Public Technologies 28 Jul 2025
Roche Holding AG published this content on July 28, 2025, and is solely ...
Edit

Roche Diagnostics showcases science-driven leadership and innovation at ADLM 2025 (Roche Holding AG)

Public Technologies 24 Jul 2025
Roche Holding AG published this content on July 24, 2025, and is solely ...
Edit

Half-Year Presentation (Roche Holding AG)

Public Technologies 24 Jul 2025
... exceed the historical published earnings or earnings per share of Roche ... Roche ... Roche Holding AG published this content on July 23, 2025, and is solely responsible for the information contained herein.
Edit

Half-Year Presentation with appendix (Roche Holding AG)

Public Technologies 24 Jul 2025
Roche ... Roche Group ... Key growth drivers of the Roche portfolio ... Roche Diagnostics Day highlights ... Roche Holding AG published this content on July 24, 2025, and is solely responsible for the information contained herein.
Edit

Half-Year Report 2025 (Roche Holding AG)

Public Technologies 24 Jul 2025
Net income attributable to Roche shareholders Diluted EPS (CHF) ... Roche Group Interim Consolidated Financial Statements 45 ... Roche Holding AG published this content on July 24, 2025, and is solely responsible for the information contained herein.
Edit

Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease (Roche Holding AG)

Public Technologies 21 Jul 2025
Roche Holding AG published this content on July 21, 2025, and is solely ...
Edit

Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma (Roche Holding AG)

Public Technologies 18 Jul 2025
Roche Holding AG published this content on July 18, 2025, and is solely ...
Edit

Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases (Roche Holding AG)

Public Technologies 07 Jul 2025
Roche Holding AG published this content on July 07, 2025, and is solely ...
Edit

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs (Roche Holding AG)

Public Technologies 07 Jul 2025
Roche Holding AG published this content on July 07, 2025, and is solely ...
Edit

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma (Roche Holding AG)

Public Technologies 20 Jun 2025
Roche Holding AG published this content on June 20, 2025, and is solely ...
Edit

Genentech Provides Update on Phase III Verona Study (Roche Holding AG)

Public Technologies 16 Jun 2025
Roche Holding AG published this content on June 16, 2025, and is solely ...
Edit

Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease (Roche Holding AG)

Public Technologies 16 Jun 2025
Roche Holding AG published this content on June 16, 2025, and is solely ...
Edit

Genentech’s Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer (Roche Holding AG)

Public Technologies 02 Jun 2025
Roche Holding AG published this content on June 02, 2025, and is solely ...
Edit

Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis (Roche Holding AG)

Public Technologies 30 May 2025
Roche Holding AG published this content on May 30, 2025, and is solely ...

Article Search

tools
×
×
×
×